Selection in Two Award Categories follows GeoVax receiving the 2018 Best Biotech Award
ATLANTA, GA, March 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB:GOVX), a biotechnology company developing human vaccines and immunotherapies using its novel viral vector platform technology, today announced its selection as a finalist in two award categories at this year's 12th Vaccine Industry Excellence (ViE) Awards program, held in conjunction with the 19th World Vaccine Congress. The Company's unique immuno-oncology product (GeoVax MVA-VLP-MUC1) was selected as a finalist for the "Best Therapeutic Vaccine Award" and GeoVax's novel MVA-VLP vaccine platform was selected as a finalist for the "Best New Vaccine Technology Award." The ViE Awards will be announced on April 15.
David Dodd, GeoVax President and CEO, commented, "We are humbled and honored to receive this high recognition of our ongoing efforts related to both our product development efforts and the recognized value of our unique platform technology and expertise. Last year, we were honored in receiving the 2018 "Best Biotech" ViE Award, and to be a finalist for the "Best Prophylactic Vaccine" for our Zika vaccine candidate. This year's selection as a finalist in two categories is further humbling, recognizing the breadth of exciting new developments underway in vaccines and immunotherapies. As we continue to successfully advance GeoVax's development programs on multiple fronts, we are focused on moving several development programs into clinical evaluation, addressing various infectious diseases and cancer indications. I want to thank our outstanding team and our many collaborators, all of whom vastly contributed to this accomplishment."
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and various cancers using its MVA-VLP vaccine platform. The Company's development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.
Contact: GeoVax Labs, Inc.firstname.lastname@example.org 678-384-7220 LinkedIn: www.linkedin.com/company/geovax-inc-/ Twitter: @Geovax_News
Source: GeoVax, Inc.